Aspirin ResistanceNCT00792272
Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients
An observational study of Aspirin Resistance, run by Northwell Health.
Trial summary
Dialysis patient could be more aspirin resistant than the general population based on data from chronic kidney disease patients Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Aspirin Resistance
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Jun 2008to Nov 2008
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: all hemodialysis patients on aspirin
Who may be able to join
- all hemodialysis patients on aspirin
Who cannot join
- low platelets <100.000
- coagulopathy, bleeding disorders
- patient on plavix
About this study
Official title: Prevalence of Aspirin Resistance in Hemodialysis Patients
Dialysis patient could be more aspirin resistant than the general population based on data from chronic kidney disease patients
Read the detailed description
We will try to describe the profile of aspirin resistant patient in hemodialysis patients
- Conditions
- Aspirin Resistance
- Keywords
- aspirin resistance, aspirin resistance in hemodialysis patients
What is being measured
The primary outcome is the main question the study is designed to answer.
Aspirin Resistance in Hemodialysis patients
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Nov 2008 (estimated)
- Study startJun 2008
- Primary completionNov 2008
- Study completionNov 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aspirin ResistanceStudies of the same condition, open and under way.
- More trials run by Northwell HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Northwell Health
- Sponsor type
- University, hospital or other
- Collaborators
- Staten Island University Hospital
- Responsible party
- Principal investigator, Suzanne El-Sayegh, Northwell Health
- Investigators
- Suzanne El-Sayegh, MD, Principal investigator, SIUH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00792272
- Sponsor's protocol ID
- 08-013
- Status last verified
- Jul 2013
- First submitted
- 14 Nov 2008
- Last updated
- 22 Jul 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Aspirin Resistance in Hemodialysis Patients
- ClinicalTrials.gov ID
- NCT00792272
- Acronym / sponsor ID
- 08-013
- Conditions
- Aspirin Resistance
- Keywords
- aspirin resistance, aspirin resistance in hemodialysis patients
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Northwell HealthUniversity, hospital or other
- Collaborators
- Staten Island University Hospital
- Study start
- Jun 2008
- Primary completion
- Nov 2008 (actual)
- Study completion
- Nov 2008 (actual)
- First posted
- 17 Nov 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dialysis patient could be more aspirin resistant than the general population based on data from chronic kidney disease patients
Detailed description
We will try to describe the profile of aspirin resistant patient in hemodialysis patients
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- all hemodialysis patients on aspirin
Key inclusion criteria (1 listed)
- all hemodialysis patients on aspirin
Key exclusion criteria (3 listed)
- low platelets <100.000
- coagulopathy, bleeding disorders
- patient on plavix
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Aspirin Resistance in Hemodialysis patients
Time frame: 2 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2013.
Related trials for Aspirin Resistance
Active, not recruitingPhase 4
Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)
Coronary Artery Disease, High On-treatment Platelet Reactivity (HTPR)
RecruitingPhase 3
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Prostate Cancer
RecruitingObservational study
Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia
Preeclampsia, Preeclampsia (PE)
RecruitingPhase 3
Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance
Myeloproliferative Neoplasms (MPN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Suzanne El-Sayegh, MD principal investigator
SIUH
Questions about this trial
What is this clinical trial studying?
An observational study of Aspirin Resistance, run by Northwell Health.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2013. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Aspirin Resistance in Hemodialysis patients (time frame: 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2013.